(Dr.Behçet Uz Çocuk Hastalığı ve Çocuk Cerrahisi Eğitim ve Araştırma Hastanesi, Neonatoloji Anabilim Dalı, İzmir, Türkiye)
(Dr.Behçet Uz Çocuk Hastalığı ve Çocuk Cerrahisi Eğitim ve Araştırma Hastanesi, Neonatoloji Anabilim Dalı, İzmir, Türkiye)
(Dr.Behçet Uz Çocuk Hastalığı ve Çocuk Cerrahisi Eğitim ve Araştırma Hastanesi, Neonatoloji Anabilim Dalı, İzmir, Türkiye)
(Dr.Behçet Uz Çocuk Hastalığı ve Çocuk Cerrahisi Eğitim ve Araştırma Hastanesi, Neonatoloji Anabilim Dalı, İzmir, Türkiye)
(Dr.Behçet Uz Çocuk Hastalığı ve Çocuk Cerrahisi Eğitim ve Araştırma Hastanesi, Neonatoloji Anabilim Dalı, İzmir, Türkiye)
(Dr.Behçet Uz Çocuk Hastalığı ve Çocuk Cerrahisi Eğitim ve Araştırma Hastanesi, Neonatoloji Anabilim Dalı, İzmir, Türkiye)
Yıl: 2020Cilt: 26Sayı: 1ISSN: 1300-4751 / 2602-4918Sayfa Aralığı: 64 - 69İngilizce

18 0
Incomplete Antenatal Steroid Therapy Can Enhance Outcomes in Preterm Infants with Emergency Conditions
OBJECTIVE: We aimed to investigate the role of incomplete of antenatal steroid therapy by comparing with no and complete steroid exposure on mortality and morbidity in preterm infants. STUDY DESIGN: This is a prospective, an observational study which includes preterm infants of 32 weeks of gestation and/or ≤1500 grams who were referred to Izmir Dr. Behcet Uz Children’s Hospital NICU during the one year period. Infants were divided into three groups according to the administration of antenatal steroid as those who received incomplete-dose antenatal steroid, complete dose steroid therapy and those with no steroid exposure. Intubation at the delivery room, surfactant requirement, the inotropic requirement in the first 72 hours and morbidities associated with prematurity were determined as the primary results. Mortality and bronchopulmonary dysplasia at discharge and stage ≥2 retinopathy were analyzed as secondary outcomes. RESULTS: We found that 54 infants were born with an incomplete dose, 55 infants with complete dose and 38 infants with no steroid therapy. Surfactant requirement, inotropic requirement, and hemodynamically significant patent ductus arteriosus were lower in the steroid exposure group leading to a statistical difference (p <0.05). Also, it was found that mortality and Bronchopulmonary dysplasia was lower in the incomplete and complete dose steroid groups, leading to a statistical difference (p <0.05). CONCLUSION: We speculate that even incomplete dose steroid may reduce mortality by reducing respiratory distress syndrome.
DergiAraştırma MakalesiErişime Açık
  • 1. Shahzad F, Umar N. Impact of antenatal corticosteroids on frequency and mortality due to respiratory distress syndrome in preterm neonates. J Ayub Med Coll Abbottabad. 2016;28(4):698-701.
  • 2. Blencowe H, Cousens S, Oestergaard MZ, Chou D, Moller AB, Narwal R, et al. National, regional, and worldwide estimates of preterm birth rates in the year 2010 with time trends since 1990 for selected countries: a systematic analysis and implications. Lancet. 2012;379(9832):2162- 72.
  • 3. Horbar JD, Carpenter JH, Badger GJ, Kenny MJ, Soll RF, Morrow KA, et al. Mortality and neonatal morbidity among infants 501 to 1500 grams from 2000 to 2009. Pediatrics. 2012;129(6):1019-26.
  • 4. Bonanno C, Wapner RJ. Antenatal corticosteroid treatment: what's happened since Drs Liggins and Howie? Am J Obstet Gynecol. 2009;200(4):448-57.
  • 5. Liggins GC, Howie RN. A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants. Pediatrics. 1972;50(4):515-25.
  • 6. Miyazaki K, Furuhashi M, Ishikawa K, Tamakoshi K, Hayashi K, Kai A, et al. Long-term outcomes of antenatal corticosteroids treatment in very preterm infants after chorioamnionitis. Arch Gynecol Obstet. 2015;292(6): 1239-46.
  • 7. Roberts D, Brown J, Medley N, Dalziel SR Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst Rev. 2017;3:CD004454.
  • 8. Ervin MG, Padbury JF, Polk DH, Ikegami M, Berry LM, Jobe AH. Antenatal glucocorticoids alter premature newborn lamb neuroendocrine and endocrine responses to hypoxia. Am J Physiol Regul Integr Comp Physiol. 2000; 279(3):R830-8.
  • 9. Greenough A. Respiratory distress syndrome. In: Rennie JM, editor. Textbook of neonatology. Londra: Churchill Livingstone; 2012. p. 468-85.
  • 10. Papile LA, Burstein J, Burstein R, Koffler H. Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1,500 gm. J Pediatr. 1978;92(4):529-34.
  • 11. Gupta A, Paria A. Etiology and medical management of NEC. Early Hum Dev. 2016;97:17-23.
  • 12. Su BH, Watanabe T, Shimizu M, Yanagisawa M. Echocardiographic assessment of patent ductus arteriosus shunt flow pattern in premature infants. Arch Dis Child Fetal Neonatal Ed. 1997;77(1):36-40.
  • 13. International Committee for the Classification of Retinopathy of Prematurity. The International Classification of Retinopathy of Prematurity revisited. Arch Ophthalmol. 2005;123(7):991-9.
  • 14. Ozkan H, Erdeve O, Kutman HGK. Turkish Neonatal Society guideline on the management of respiratory distress syndrome and surfactant treatment. Turk Pediatr Ars. 2018;53(Suppl 1):S45-S54.
  • 15. Lau HCQ, Tung JSZ, Wong TTC, Tan PL, Tagore S. Timing of antenatal steroids exposure and its effects on neonates. Arch Gynecol Obstet. 2017;296(6):1091-6.
  • 16. Schmidt AF, Kemp MW, Rittenschober-Böhm J, Kannan PS, Usuda H, Saito M, et al. Low-dose betamethasone-acetate for fetal lung maturation in preterm sheep. Am J Obstet Gynecol. 2018;218(1):132.e1-132.e9.
  • 17. Salhab WA, Hynan LS, Perlman JM. Partial or complete antenatal steroids treatment and neonatal outcome in extremely low birth weight infants<or =1000 g: is there a dose-dependent effect? J Perinatol. 2003;23(8):668-72.
  • 18. Alkan Ozdemir S, Arun Ozer E, Bakiler AR, Ilhan O, Sutcuoglu S, Tatli MM. Assessment of hemodynamic changes in preterm infants with respiratory distress syndrome. Anatol J Cardiol. 2017;18(6):440.
  • 19. Clyman RI, Ballard PL, Sniderman S, Ballard RA, Roth R, Heymann MA, et al. Prenatal administration of betamethasone for prevention of patient ductus arteriosus. J Pediatr. 1981;98(1):123-6.
  • 20. Sweet DG, Carnielli V, Greisen G, Hallman M, Ozek E, Plavka R, et al. European Consensus Guidelines on the Management of Respiratory Distress Syndrome-2016 Update. Neonatology. 2017;111(2):107-25.
  • 21. Travers CP, Carlo WA, McDonald SA, Das A, Bell EF, Ambalavanan N, et al. Mortality and pulmonary outcomes of extremely preterm infants exposed to antenatal corticosteroids. Am J Obstet Gynecol. 2018;218(1):130.e1- 130.e13.
  • 22. Carlo WA, McDonald SA, Fanaroff AA, Vohr BR, Stoll BJ, Ehrenkranz RA, et al. Association of antenatal corticosteroids with mortality and neurodevelopmental outcomes among infants born at 22 to 25 weeks’ gestation. JAMA. 2011;306(21):2348-58.
  • 23. Wong D, Abdel-Latif M, Kent A; NICUS Network. Antenatal steroid exposure and outcomes of very premature infants: a regional cohort study. Arch Dis Child Fetal Neonatal Ed. 2014;99(1):12-20.
  • 24. Mori R, Kusuda S, Fujimura M; Neonatal Research Network Japan. Antenatal corticosteroids promote survival of extremely preterm infants born at 22 to 23 weeks of gestation. J Pediatr. 2011;159(1):110-114.e1.

TÜBİTAK ULAKBİM Ulusal Akademik Ağ ve Bilgi Merkezi Cahit Arf Bilgi Merkezi © 2019 Tüm Hakları Saklıdır.